LONG MINI-FUTURE - MODERNA | Market Closed - Euronext Paris 17:30:00 14/06/2024 BST | ||
| 3.645 EUR | -14.03% |
|
| Current month | -2.55% | ||
| 1 month | +40.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 3.825 | -9.79% |
| 13/06/24 | 4.24 | -3.85% |
| 12/06/24 | 4.41 | -1.78% |
| 11/06/24 | 4.49 | +2.28% |
| 10/06/24 | 4.39 | -9.86% |
Real-time Euronext Paris
Last update June 14, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| XQ71V | |
| ISIN | DE000VD417K6 |
| Date issued | 30/04/2024 |
| Strike | 101.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.48 € |
|---|---|
| Lowest since issue | 0.01 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Certificates
- XQ71V Certificat